CNMD  Conmed Corporation

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

1.090B

Vuru Grade

44.54/100

Current Price

$39.87
+0.53 (+1.35%)

Growth Price

$42.39
Undervalued by 6.33%

Stability Price

$18.87
Overvalued by 52.67%

Company Metrics

  • 31.50 P/E
  • 1.44 P/S
  • 1.79 P/B
  • 1.249 EPS
  • 5.79% Cash ROIC
  • 0.49 Cash Ratio
  • 0.75 / 1.91 % Dividend
  • 236,948.00 Avg. Vol.
  • 27.34M Shares
  • 1.090B Market Cap.

Company Description

CONMED Corporation, a medical technology company, provides surgical devices and equipment for minimally invasive procedures and monitoring. The company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery, and endoscopic technologies. It offers arthroscopy products, including powered resection instruments, art...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

CONMED Corporation Announces Leadership Transition
CNNMoney - Jul 23, 2014
UTICA, N.Y., July 23, 2014 (GLOBE NEWSWIRE) -- CONMED Corporation (Nasdaq:CNMD) today announced that Joseph Corasanti is stepping down as Chief Executive Officer, President and a member of the Board of Directors, effective immediately.
CONMED Corporation Announces Second Quarter 2014 Financial Results - Wall Street Journal
Conmed founder Eugene Corasanti retires and son steps down as president in ... - Greenfield Daily Reporter
Top Decliners in Focus: Unisys Corporation (UIS), CONMED Corporation ...
Investor Wired - Jul 23, 2014
CONMED Corporation (NASDAQ:CNMD) plummeted over 12 percent in the current trading session after the medical technology company announced that its chief executive officer, Joseph Corasanti is resigning from his position.
ConMed restructures leadership; no sale planned
Utica Observer Dispatch - Jul 23, 2014
Robert Shallish, ConMed's chief financial officer and vice president of finance, said the departure of the Corasantis is not related to the discord that arose in November when Voce Capital, which reportedly owns less than 1 percent of the company ...
CONMED Leadership Transitions & Strategy Update - HealthpointCapital
CONMED Corporation to Announce Second Quarter 2014 Financial Results on ...
Wall Street Journal - Jul 2, 2014
UTICA, NY--(Marketwired - Jul 2, 2014) - CONMED Corporation (NASDAQ: CNMD) announced today that it expects to report second quarter 2014 financial results before the market opens on Wednesday, July 23, 2014, and will also hold a conference call live ...
CONMED Lags on Q2 Earnings & Revenues, Cuts View - Analyst Blog
NASDAQ - Jul 24, 2014
CONMED Corporation ( CNMD ) posted adjusted earnings per share of 47 cents for the second quarter of 2014, up 9.3% from 43 cents recorded in the same quarter of 2013.
Conmed Becomes Oversold
Forbes - Jul 23, 2014
But making Conmed Corp. an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of CNMD entered into oversold territory, changing hands as low as $36.495 per share.
CONMED (CNMD) in Focus: Stock Tumbles 9.3%
Zacks.com - Jul 24, 2014
CONMED Corporation (CNMD - Analyst Report) saw a big move last session, as the company's shares fell by over 9% on the day.
Notable Movers: Integra Lifesciences Holdings (NASDAQ:IART), CONMED ...
Crazy Joys - Jul 5, 2014
On 19 june 2014 Integra LifeSciences Holdings Corporation (Nasdaq:IART), a world leader in medical technology, announced that June 2014 marks the 25th anniversary of its founding.
CONMED (CNMD) in Focus: Stock Tumbles 9.3% - Tale of the Tape
NASDAQ - Jul 24, 2014
CONMED Corporation ( CNMD ) saw a big move last session, as the company's shares fell by over 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session.
US Hot Stocks: Northrop Grumman (NYSE:NOC), CONMED (NASDAQ:CNMD ...
eMarketsDaily - Jul 24, 2014
Northrop Grumman Corporation (NYSE:NOC) [Trend Analysis] released its second quarter (Jun) earnings of $2.37 per share, $0.15 improved than the Capital IQ Consensus Estimate of $2.22.